Market Research Reports and Industry Reports

Meningioma - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Meningioma - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Meningioma - Pipeline Review, H2 2017, provides an overview of the Meningioma (Oncology) pipeline landscape.

A meningioma is a type of tumor that develops from the meninges, the membrane that surrounds the brain and spinal cord. There are three layers of meninges, called the dura mater, arachnoid and pia mater. Most meningiomas (90%) are categorized as benign tumors, with the remaining 10% being atypical or malignant. There is no obvious cause of a meningioma. However, this type of brain tumor is about three times more common in women than in men. A meningioma can cause symptoms by pressing on the brain or spinal cord.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Meningioma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Meningioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Meningioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Meningioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0 and Preclinical stages are 8, 3, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Meningioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Meningioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Meningioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Meningioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Meningioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Meningioma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Meningioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Meningioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Meningioma - Overview 7
Meningioma - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 12
Meningioma - Therapeutics Assessment 13
Assessment by Target 13
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Meningioma - Companies Involved in Therapeutics Development1
Arno Therapeutics Inc1
AstraZeneca Plc1
Boehringer Ingelheim GmbH2
Eli Lilly and Co2
Genentech Inc2
GlaxoSmithKline Plc3
Merck & Co Inc3
Merck KGaA4
Novartis AG4
Ono Pharmaceutical Co Ltd5
Pharma Mar SA5
Progenics Pharmaceuticals Inc6
Meningioma - Drug Profiles7
abemaciclib - Drug Profile7
Product Description7
Mechanism Of Action7
R&D Progress7
afatinib dimaleate - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
AR-42 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
avelumab - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Edotreotide Labeled Yttrium 90 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
GSK-2256098 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
HXR-9 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
nitrosylcobalamin - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
nivolumab - Drug Profile 73
R&D Progress 74
pasireotide ER - Drug Profile 126
Product Description 126
Mechanism Of Action 126
R&D Progress 126
pembrolizumab - Drug Profile 129
R&D Progress 130
selumetinib sulfate - Drug Profile 198
Product Description 198
Mechanism Of Action 198
R&D Progress 198
trabectedin - Drug Profile06
Product Description06
Mechanism Of Action06
R&D Progress06
Vaccine to Target VEGFR1 and VEGFR2 for Oncology - Drug Profile14
Product Description14
Mechanism Of Action14
R&D Progress14
vismodegib - Drug Profile15
Product Description15
Mechanism Of Action15
R&D Progress15
vistusertib - Drug Profile21
Product Description21
Mechanism Of Action21
R&D Progress21
Meningioma - Dormant Projects24
Meningioma - Discontinued Products25
Meningioma - Product Development Milestones26
Featured News & Press Releases26
Sep1,015: Enrollment of first patient in a Phase II trabectedin study in brain tumor type called meningioma26
Jun 07,012: Arno Therapeutics Announces Additional Orphan-Drug Designations For AR-42 In Europe26
Feb1,012: Arno Therapeutics Receives Two Orphan-Drug Designations For AR-42 To Treat Central-Nervous-System Tumors27
Appendix28
Methodology28
Coverage28
Secondary Research28
Primary Research28
Expert Panel Validation28
Contact Us28
Disclaimer29

List Of Tables

List of Tables
Number of Products under Development for Meningioma, H2 2017 8
Number of Products under Development by Companies, H2 2017 9
Number of Products under Development by Universities/Institutes, H2 2017 10
Products under Development by Companies, H2 2017 11
Products under Development by Universities/Institutes, H2 2017 12
Number of Products by Stage and Target, H2 2017 14
Number of Products by Stage and Mechanism of Action, H2 2017 16
Number of Products by Stage and Route of Administration, H2 2017 18
Number of Products by Stage and Molecule Type, H2 2017 20
Meningioma - Pipeline by Arno Therapeutics Inc, H2 2017 21
Meningioma - Pipeline by AstraZeneca Plc, H2 2017 21
Meningioma - Pipeline by Boehringer Ingelheim GmbH, H2 2017 22
Meningioma - Pipeline by Eli Lilly and Co, H2 2017 22
Meningioma - Pipeline by Genentech Inc, H2 2017 23
Meningioma - Pipeline by GlaxoSmithKline Plc, H2 2017 23
Meningioma - Pipeline by Merck & Co Inc, H2 2017 24
Meningioma - Pipeline by Merck KGaA, H2 2017 24
Meningioma - Pipeline by Novartis AG, H2 2017 25
Meningioma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 25
Meningioma - Pipeline by Pharma Mar SA, H2 2017 26
Meningioma - Pipeline by Progenics Pharmaceuticals Inc, H2 2017 26
Meningioma - Dormant Projects, H2 2017 224
Meningioma - Discontinued Products, H2 2017 225

Meningioma - Pipeline Review, H2 2017

Meningioma - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Meningioma - Pipeline Review, H2 2017, provides an overview of the Meningioma (Oncology) pipeline landscape.A

USD 2000View Report

Meningioma - Pipeline Review, H1 2017

Meningioma - Pipeline Review, H1 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Meningioma - Pipeline Review, H1 2017, provides an overview of the Meningioma (Oncology) pipeline landscape.A

USD 2000View Report

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2017

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2017According to the recently published report Protein Phosphatase 2A - Pipeline Review, H2 2017; Protein Phosphatase 2A (PP2A or

USD 3500View Report

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Pipeline Review, H2 2017

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Pipeline Review, H2 2017Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or

USD 3500View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)


+91 9987 2952 42

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Nov 2017
No. of Pages :229
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube